What is the purpose of this trial?
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Ages: 45 years and older
National Institute of Neurological Disorders and Stroke
Start Date: 11/27/2018
End Date: 01/18/2022
Last Updated: 12/17/2018
Study HIC#: 2000024124